Purpose: To determine the prevalence of vitreomacular interface (VMI) pathology, using spectral-domain optical coherence tomography (SD-OCT). Methods: VMI status was classified into macular posterior vitreous detachment (PVD), focal vitreomacular adhesion (VMA; ≤1,500 μm), broad VMA (>1,500 μm), focal vitreomacular traction (VMT; ≤1,500 μm), broad VMT (>1,500 μm), full-thickness macular hole (FTMH) with the presence of VMT, and FTMH without the presence of VMT. Results: A total of 1,976 eyes were included. A nonpathologic VMI was observed in 1,875 eyes (94.8%), including 1,050 (53.1%) with PVD, 120 (6.1%) with focal VMA and 705 (35.6%) with broad VMA. A pathologic state of the VMI was diagnosed in 101 eyes (5.1%). Thirty-three eyes (1.7%) were classified as focal VMT, 29 (1.4%) as broad VMT, 39 (1.9%) as FTMH, resulting in 6 small, 12 medium and 21 large FTMHs, six eyes had VMT associated to FTMH. Conclusions: Even in a tertiary care, retinal referral practice, VMI pathology is a relatively rare condition. There was a higher prevalence in a tertiary hospital study compared to population-based studies.

1.
Shao L, Wei W: Vitreomacular traction syndrome. Chin Med J (Engl) 2014;127:1566-1571.
2.
García-Layana A, García-Arumí J, Ruiz-Moreno JM, Arias-Barquet L, Cabrero-López F, Figueroa MS: A review of current management of vitreomacular traction and macular hole. J Ophthalmol 2015;2015:809640.
3.
Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA: Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012;367:606-615.
4.
Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P: The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 2013;120:2611-2619.
5.
Bottós JM, Elizalde J, Rodrigues EB, Maia M: Current concepts in vitreomacular traction syndrome. Curr Opin Ophthalmol 2012;23:195-201.
6.
Mojana F, Kozak I, Oster SF, Cheng L, Bartsch DU, Brar M, Yuson RM, Freeman WR: Observations by spectral-domain optical coherence tomography combined with simultaneous scanning laser ophthalmoscopy: imaging of the vitreous. Am J Ophthalmol 2010;149:641-650.
7.
Dimopoulos S, Bartz-Schmidt KU, Gelisken F, Januschowski K, Ziemssen F: Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to Ocriplasmin therapy? Br J Ophthalmol 2015;99:350-353.
8.
Duker JS, Moshfeghi AA: Ocriplasmin: a medical or surgical therapy? Retina 2013;33:2001-2002.
9.
Stalmans P, Duker JS, Kaiser PK, Heier JS, Dugel PU, Gandorfer A, Sebag J, Haller JA: OCT-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina 2013;33:2003-2011.
10.
Haller JA, Stalmans P, Benz MS, Gandorfer A, Pakola SJ, Girach A, Kampik A, Jaffe GJ, Toth CA: Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion. Ophthalmology 2015;122:117-122.
11.
Meuer SM, Myers CE, Klein BE, Swift MK, Huang Y, Gangaputra S, Pak JW, Danis RP, Klein R: The epidemiology of vitreoretinal interface abnormalities as detected by spectral-domain optical coherence tomography. Ophthalmology 2015;122:787-795.
12.
Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P: Symptomatic vitreomacular adhesion. Retina 2013;33:1503-1511.
13.
McCannel CA, Ensminger JL, Diehl NN, Hodge DN: Population based incidence of macular holes. Ophthalmology 2009;116:1366-1369.
14.
Wang S, Xu L, Jonas JB: Prevalence of full-thickness macular holes in urban and rural adult Chinese: The Beijing Eye Study. Am J Ophthalmol 2006;141:589-591.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.